Question 1

How will the results of the tumor autoantibody tests affect my treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC clinical trial (NCT04372732). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential risks or side effects of participating in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC clinical trial (NCT04372732). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this study compare to other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC clinical trial (NCT04372732). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the process of testing for tumor autoantibodies involve?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC clinical trial (NCT04372732). Contact the study team or your healthcare provider for specific answers.

Question 5

How often will I need to visit for tests or treatment if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC clinical trial (NCT04372732). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if the tumor autoantibody tests show that I might not benefit from PD-1 therapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC clinical trial (NCT04372732). Contact the study team or your healthcare provider for specific answers.

What this study is about